度伐利尤单抗联合PP化疗方案治疗Ⅲ期非小细胞肺癌患者的效果  

Effects of Durvalumab combined with PP chemotherapy regimen in treatment of patients with stage III non-small cell lung cancer

作　　者：王艳杰[1] 潘春香[1] 胡祥坤[1] 孙如坤[1] 鹿敏 WANG Yanjie;PAN Chunxiang;HU Xiangkun;SUN Rukun;LU Min(Department of Respiratory and Critical Care Medicine of Zhoukou Central Hospital,Zhoukou 466000 Henan,China)

机构地区：[1]周口市中心医院呼吸与危重症医学科,河南周口466000

出　　处：《中国民康医学》2024年第12期39-41,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察度伐利尤单抗联合PP化疗方案治疗Ⅲ期非小细胞肺癌(NSCLC)患者的效果。方法:回顾性分析2021年5月至2023年5月该院收治的66例Ⅲ期NSCLC患者临床资料,按治疗方案不同将其分为观察组和对照组各33例。对照组采用PP化疗方案治疗,观察组在对照组基础上联合度伐利尤单抗注射液治疗,比较两组疾病缓解率、KPS评分、癌症治疗功能评价系统-肺癌模块(FACT-L)评分、血清生化因子[Ⅳ型胶原蛋白α3(COL4A3)、G蛋白偶联受体相关分选蛋白1(GASP-1)]水平和不良反应发生率。结果:观察组疾病缓解率为60.61%,明显高于对照组的36.36%,差异有统计学意义(P<0.05);治疗后,两组KPS评分高于治疗前,且观察组高于对照组,两组FACT-L评分和血清COL4A3、GASP-1水平低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);治疗期间,两组腹泻、脱发、骨髓抑制、恶心等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:度伐利尤单抗联合PP化疗方案治疗Ⅲ期NSCLC患者可提高疾病缓解率和KPS评分,降低FACT-L评分及血清COL4A3、GASP-1水平,效果优于单纯PP化疗方案治疗。Objective:To observe effects of Durvalumab combined with PP chemotherapy regimen in treatment of patients with stage III non-small cell lung cancer(NSCLC).Methods:The clinical data of 66 patients with stage III NSCLC admitted to this hospital from May 2021 to May 2023 were retrospectively analyzed.According to different treatment options,they were divided into observation group and control group,33 cases in each group.The control group was treated with PP chemotherapy regimen,while the observation group was treated with Durvalumab injection on the basis of that of the control group.The disease remission rate,the KPS score,the functional assessment of cancer therapy-lung(FACT-L)score,the serum biochemical factors[type IV collagenα3(COL4A3),G protein-coupled receptor-associated sorting protein 1(GASP-1)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The disease remission rate of the observation group was 60.61%,which was significantly higher than that of the control group(36.36%),and the difference was statistically significant(P<0.05).After the treatment,the KPS scores of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the FACT-L score and the serum COL4A3 and GASP-1 levels in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).During the treatment,there was no significant difference in the incidence of adverse reactions such as diarrhea,alopecia,bone marrow suppression,nausea between the two groups(P>0.05).Conclusions:Durvalumab combined with PP chemotherapy regimen in the treatment of the patients with stage III non-small cell lung cancer can improve the disease remission rate and the KPS scores,and reduce the FACT-L scores and the serum COL4A3 and GASP-1 levels.Moreover,it is superior to single PP chemotherapy regimen treatment.

关 键 词：非小细胞肺癌 度伐利尤单抗 PP化疗方案 疾病缓解率 KPS评分 COL4A3 GASP-1 

分 类 号：R734.2[医药卫生—肿瘤]